Skip to main content

Advertisement

Table 1 Clinicopathological characteristics of the 152 breast cancer patients

From: Tumor expression, plasma levels and genetic polymorphisms of the coagulation inhibitor TFPI are associated with clinicopathological parameters and survival in breast cancer, in contrast to the coagulation initiator TF

Characteristic Number (%)
Gender  
 Female 152 (100)
 Male 0 (0)
Age  
 ≤55 80 (52.6)
 >55 72 (47.4)
 Mean (±SD) 56.0 (12.4)
Tumor size (T-status)  
 T1 (0–20 mm) 77 (50.7)
 T2 (20–50 mm) 68 (44.7)
 T3 (>50 mm) 7 (4.6)
 (T2-T3) (75 (49.3))
Grade  
 G1 (well differentiated) 21 (13.8)
 G2 (moderately differentiated) 53 (34.9)
 (G1-G2) (74 (48.7))
 G3 (poorly differentiated) 78 (51.3)
Estrogen receptor (ER) status  
 Negative 35 (23.0)
 Positive 117 (77.0)
Progesterone receptor (PR) status  
 Negative 51 (33.6)
 Positive 101 (66.4)
Human epidermal growth factor receptor 2 (HER2) status
 Negative 137 (90.1)
 Positive 15 (9.9)
Hormone receptor (HR) negative status (ER/PR negative)
 Yes 34 (22.4)
 No 118 (77.6)
Triple negative (TN) status (ER/PR/HER2 negative)  
 Yes 29 (19.1)
 No 123 (80.9)
Lymph node (N) status  
 N0 (0 lymph nodes) 98 (64.5)
 N1 (1–3 lymph nodes) 40 (26.3)
 N2 (4–9 lymph nodes) 11 (7.2)
 N3 (≥10 lymph nodes) 3 (2.0)
 (N1-N2-N3)a (54 (35.5))
Molecular tumor subtypes (PAM50 signatures)  
 Basal 25 (16.7)
 HER2 enriched 15 (10.0)
 Luminal A 63 (42.0)
 Luminal B 39 (26.0)
 Normal-like 8 (5.3)
  1. aLymph node positive group.